ESTRO 38 Abstract book

S373 ESTRO 38

VS evaluation showed reduced vocal cord motion in 50% of LM group and 10% of RT group and incomplete glottic closure in 100% of LM group and 40% of RT group. In the table we reported the vocal acoustic analysis and VS evaluation in both groups.

Conclusion Selective SPECT/CT-guided ENI decreased acute dysphagia, feeding tube placement, and late xerostomia, compared to conventional bilateral ENI. Additionally, it resulted in shorter duration of acute toxicity in general. PO-0727 Voice outcome following radiotherapy or laser microsurgery in patients with early glottic cancer A. Allajbej 1 , F. Patani 2 , S. Di Biase 2 , D. Fasciolo 2 , C. Di Carlo 2 , C. Rosa 2 , L. Gasparini 2 , M. Di Francesco 3 , G. Falcone 4 , G. Quaternato 5 , A. Croce 5 , A. Di Pilla 2 , M. Trignani 2 , L. Caravatta 2 , D. Genovesi 2 1 SS.Annunziata, Radiotherapy, Chieti, Italy ; 2 SS Annunziata, Radiotherapy, Chieti, Italy ; 3 Papa Paolo VI Fondation, Speech rehabilitation, Chieti, Italy ; 4 Papa Paolo VI Fondation, Phoniatrics, Chieti, Italy ; 5 SS Annunziata, Otorhinolaryngology, Chieti, Italy Purpose or Objective Oncological outcome of patients affected by early glottic cancer (EGC) treated with radiotherapy (RT) either Laser Microsurgery (LM) is similar, but it is not clear if and how these treatment modalities could differ in terms of voice quality (VQ) outcome and voice handicap. Prospective randomized studies comparing vocal outcomes following RT vs LM are lacking and voice evaluation methodology during follow-up is often not well structured. The aim of our study is to report clinical outcomes, focalizing on voice quality of patients who received either RT or LM. Material and Methods We evaluated 45 EGC patients (Tis, T1 and T2 stages) submitted to primary RT or LM between 2008-2017. Overall survival (OS), progression free survival (PFS) and radiation induced toxicities according to CTCAE v. 4.0 scale were evaluated. For a subsample of this ECG population a multi-modality VQ analysis was performed. Voice evaluation includes: Voice Handicap Index (VHI-30), objective analysis using PRAAT software and perceptual rating performed by speech therapist (GRBAS scale). A clinical examination was performed jointly with radiation oncologist, otolaryngologist and speech pathologist, involving laryngeal evaluation with videostroboscope (VS) and laryngoscope Results A total of 30 patients, average age of 74 years (range 54- 86), received RT with a total dose of 66-70 Gy, 2 Gy/day, using 3-dimensional conformal technique. 15 patients received LM. Overall tumor stage distribution was: Tis (8.9 %), T1 (86.7%), and T2 (4.4%). The median follow-up was 40.5 months (range 6-115 months). OS and PFS were 96.6% and 96.6% for RT group and 93.3% and 86.7% for LM group; from the original sample of 45 patients, in the context of ongoing VQ analyses 16 patients were evaluated to date. VHI-30 scores showed a mild (25.5) and severe (73.6) voice disability for RT and LM groups, respectively. Regarding GRBAS scale voice dysfunction in the LM group tends to be more moderate (67%) than severe (33%) whereas in the RT group tends to be more mild (40%) than moderate (20%).

Conclusion EGC patients can benefit from LM or RT both aimed to obtain organ and function preservation; as patients submitted to RT or LM can achieve similar OS and PFS rates, it is all about vocal “performance”. Preliminary results from the recorded data (VHI-30, GRBBAS scale and PRAAT analysis) seem to show a more favorable voice outcome in RT patients vs LM. The study is still ongoing; we attempt to recruit more patients, so then statistical analysis will be performed in order to compare clinical and voice outcome in two treatment modalities (RT and LM) and to confirm these results. PO-0728 reirradiation of salivary gland tumors with carbon ion radiotherapy (CIRT) at CNAO B. Vischioni 1 , B. Dhanireddy 2 , M. Bonora 1 , S. Ronchi 1 , V. Vitolo 1 , M.R. Fiore 1 , E. D'Ippolito 1 , R. Petrucci 1 , C. Severo 3 , E. Ciurlia 4 , A. Hasegawa 5 , A. Iannalfi 1 , F. Valvo 1 , R. Orecchia 1,6 1 National Center of Oncological Hadrontherapy, Radiotherapy Unit, Pavia, Italy ; 2 Post Graduate Institute of Medical Education and Research PGIMER, Department of Radiation Oncologyst, Chandigarh, India ; 3 University of Messina, Radiation therapy Unit, Messina, Italy ; 4 Ospedale Vito Fazzi, Radiation therapy Unit, Lecce, Italy ; 5 Osaka Heavy Ion Therapy Center, Radiation therapy Unit, Osaka, Japan ; 6 European Institute of Oncology, Radiation therapy Unit, Milan, Italy Purpose or Objective to report oncologic and functional outcomes of carbon ion radiotherapy (CIRT) in re-radiation setting for recurrent salivary gland tumors at CNAO. Material and Methods From november 2013 to december 2016 patients (pts) with recurrent salivary gland tumors were enrolled in a phase- II protocol (CNAO-S14) to evaluate outcome of CIRT in the setting of carbon ions head and neck re-radiation in terms of toxicity and tumor control. Results A total of 51 pts enrolled on the protocol were recurrent salivary gland tumors. Pts median age was 60 years (± 14.34), 53% males and 47% females. Majority of pts (74.5%) had adenoid cystic carcinoma, rcT4a (51%) and rcT4b (37%) stage, 90% without clinically diagnosed nodal